Press Releases
VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to be a guest speaker at MSC 2015 Adult Stem Cell Therapy & Regenerative Medicine Conference in Cleveland, OH along with two fellow Stem Cell practitioners.
2015-08-14 --
Dr Robert Harman (DVM), Founder and CEO of Regenerative Veterinary Medicine company VetStem Biopharma, Inc. is scheduled to be a guest speaker at MSC 2015 Innovations in Cell-Based Regenerative Therapies in Cleveland, OH along with Dr Jamie Gaynor (DVM, DACVA, DACVPM) and Dr Scott Gustafson (DVM, DACVS).
The conference will offer a forum for the scientific exchange and discussion of research, ideas, and cutting-edge breakthroughs in translational regenerative medicine. The topics that will be covered in this conference range from basic discovery through model validation, clinical product development, and therapeutic application. Dr. Harman is scheduled to present on August 19th along with Dr Gaynor and Dr Gustafson. They will be presenting on Mesenchymal Stem Cell’s in Veterinary Medicine.
Dr Harman pulls from his biotechnology and veterinary experience to help VetStem perfect the clinical application of stem cell therapy for various types of injuries, illnesses, and other healing-promoting applications. VetStem is leading in the development for regenerative medicine in the veterinary field, with over 11,000 animals treated in the last 12 years.
Dr. Gaynor, a noted anesthesiologist and pain management specialist, has been involved in Regenerative Medicine since 2006. He has treated over 100 patients and been involved in three canine studies in the use of MSC’s for the treatment of osteoarthritis. Dr Gaynor has lectured nationally on the use of stem cells in veterinary medicine.
Dr. Gustafson has lectured nationally in stem cell therapy and has performed clinical stem cell therapy for 7 years. In 2007 Dr. Gustafson was credentialed with VetStem, in the use of Regenerative Veterinary Medicine for arthritis, ligament and tendon injuries, and joint. To date he has provided over 50 stem cell treatments for dogs. He has also participated in VetStem’s clinical trials.
VetStem first pioneered stem cell therapy for use in horses for tendon injuries, as an alternative to other choices such as euthanasia. Just two years after the first horse was treated, VetStem treated the first cat and dog.
In 2007 the first peer reviewed, randomized, double-blinded, placebo controlled, multi-center study was published proving intra-articular injection of VetStem processed adipose derived stem cells in the hip joint of a dog decreased patient discomfort and increased patient functional ability. That same year VetStem brought to market the Genesis Platelet Rich Plasma concentration system, as well as the first formal small animal stem cell credentialing course. In 2015, VetStem (now VetStem Biopharma) has announced the successful completion of a pilot efficacy study for allogeneic stem cell therapy (93 dogs, multi-center, blinded, placebo controlled) in support of an FDA INAD. Primary end point was statistically significant. The study will be submitted for peer reviewed publication.
“The opportunity to speak at such a prestigious conference is an honor and further recognition by the human regenerative medicine community of the significant progress and insights we (veterinarians) have contributed to the field of regenerative medicine over the past 12 years, with over 11,000 animal patients treated”, stated Dr Harman.
About VetStem Biopharma
VetStem Biopharma is a veterinarian lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 12 years and 11,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, Vet-Stem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.
